The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care

Currently, there are no data available comparing cost-effectiveness of two antidepressants in the primary care setting in the UK. Alongside a randomized, double-blind, 24-week study of mirtazapine and paroxetine, data were prospectively collected on patientsʼ use of hospital and non-hospital service...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International clinical psychopharmacology 2004-05, Vol.19 (3), p.125-134
Hauptverfasser:	Romeo, Renee, Patel, Anita, Knapp, Martin, Thomas, Christine
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antidepressive Agents - economics Antidepressive Agents - therapeutic use Biological and medical sciences Cost-Benefit Analysis Depressive Disorder - drug therapy Depressive Disorder - economics Double-Blind Method Female Fundamental and applied biological sciences. Psychology Humans Male Medical sciences Mianserin - analogs & derivatives Mianserin - economics Mianserin - therapeutic use Middle Aged Neuropharmacology Paroxetine - economics Paroxetine - therapeutic use Pharmacology. Drug treatments Primary Health Care - economics Prospective Studies Psychiatric Status Rating Scales Psychology. Psychoanalysis. Psychiatry Psychology. Psychophysiology Quality of Life Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!